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HUMAN MESENCHYMAL STROMAL CELLS ENHANCE METASTASIS OF
NEUROBLASTOMA VIA SDF-1/CXCR4 AND SDF-1/CXCR7 AXES
Ma, M., Chan, G.C.-F. The University of Hong Kong, Hong Kong SAR,
China
Background: Bone marrow is a frequent metastatic site for neuro-
blastoma, a common form of childhood cancer with poor progno-
sis. The SDF-1/CXCR4 axis has been proposed as an important
pathway during metastasis of neuroblastoma. But the role of
mesenchymal stromal cells (MSCs) and CXCR7, the other known
receptor for SDF-1, in metastatic neuroblastoma is yet to be
clarified.
Materials & Methods: In this study, we investigated the chemo-
tactic effects of human bone marrow derived MSCs on the migra-
tion of neuroblastma cells, with specific emphasis on the SDF-1/
CXCR4 and SDF-1/CXCR7 axes. To determine the contribution
of SDF-1 released by MSCs, we collected serum poor conditioned
media from three different MSC cultures and estimated their
SDF-1 levels by ELISA. We then examined the cell surface ex-
pression of CXCR4 and CXCR7 on five known neuroblastoma
cell lines (BE2C, BE2M17, IMR32, SK-N-LP and SY5Y) with
metastatic potential by flow cytometer. The metastatic functional
assessment was performed by transwell migration and invasion
assay.
Results: SDF-1 can be identified from the MSCs culture medium.
The migration and invasion of neuroblastoma was enhanced by
either MSCs co-culture or SDF-1 under transwell migration and
invasion assay. Flow cytometry analysis revealed that all of the
five cell lines expressed CXCR7, and four of them expressed
CXCR4. The migration efficiency of neuroblastoma cells in
response to either MSCs conditioned media or SDF-1 treatments
was considerably higher than that to control medium (n 5 3, p\
0.01), and such effect could be significantly blocked by
AMD3100, an inhibitor of CXCR4.
Conclusion: Our preliminary data suggested that MSCs enhanced
neuroblastoma cells migration and invasion and this is probably
acting through the SDF-1/CXCR4 and SDF-1/CXCR7 axes.187
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Background: Bone marrow derived mesenchymal cells and stem
cells are potential to differentiate into mature cells of various organs.
Here we describe the initial results of study which suggests that these
cells transformed to hepatocytes.
Methods: In this prospective, single-center study during 18 months,
liver biopsy were obtained from 9 patients who had undergone Co-
Transplantation of Mesenchymal and Hematopoietic Stem Cell for
beta thalassemia major class III. Five female patients and 4 male
patients had received transplant from their sex mismatch donors.
The biopsies were studied for the presence of donor-derived hepato-
cytes with the use of fluorescence in situ hybridization (FISH) and
immunohistochemical staining (IHC) for CD45 (leukocyte common
antigen), and a hepatocyte-specific antigen.
Results: According to sex mismatch transplantation, mixed donor-
recipient XY-positive hepatocytes in liver specimen means that
new chimer stem cells were originated from donor cells. These cells
accounted for 8 to 70 percent of the cells on FISH slides and their
hepatocyte properities were shown by IHC methods.
Conclusions:Co-transplantation of Mesenchymal and Hematopoi-
etic Stem Cell can enhance regeneration of mature hepatocytes in
liver tissue.188
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Shwachman-Diamond Syndrome (SDS) is an inherited marrow
failure disorder characterized by varying cytopenias, pancreatic dys-
function, and metaphyseal dysostosis. Neutropenia plays a crucial
role in the occurrence of recurrent and severe infectious complica-
tions representing one of the major causes of death in SDS patients.
The aim of our study is to better comprehend the marrow dysfunc-
tion occurring in SDS patients, by analyzing the functional proper-
ties of bone marrow (BM)-derived mesenchymal stem cells (MSCs).
After informed consent, BM cells obtained from 16 SDS patients
were plated in sterile tissue culture flasks. At the third passage of
the culture, cells were tested for the expression of specific surface
markers, their ability to differentiate into mesengenic lineages, their
capability to abrogate T cell proliferation and their capacity to
prevent neutrophils apoptosis. MSCs derived from SDS patients
(SDS-MSCs) displayed typical fibroblastoid morphology; they
were consistently devoid of contaminating hematopoietic cells, be-
ing negative for CD34, CD45, HLA-DR, CD11b, CD19, and
CD14, but expressed common MSC markers including CD90,
CD73, CD105 and HLA-ABC. Similarly to MSCs obtained from
healthy donors (HD-MSCs), these cells were able to differentiate
into adipocytes and osteoblasts. In addition, SDS-MSCs drastically
decreased the mitogen-induced lymphocyte proliferation, in a dose
dependent manner. We also cultured neutrophils obtained from
HDs in presence or absence of MSCs at different time points. We
demonstrated that SDS-MSCs were comparable to HD-MSCs in
supporting the viability of neutrophils. Importantly, SDS-MSC
were able to produce high amount of IL-6 (mean 5 2658 pg/ml,
range5 2086-3229 pg/ml), a crucial cytokine involved in the protec-
tion of neutrophils from apoptosis.In conclusion, we successfully iso-
lated and characterizedMSCs from SDSpatients. These cells did not
show any significant differences from HD-MSCs. Further studies
are needed to better comprehend the functional and molecular fea-
tures of SDS-MSCs, which are potentially involved in the hemato-
logical abnormalities typical of SDS patients.189
STROMAL STEM CELL THERAPY FOR PROPHYLAXIS OF ACUTE GVHD:
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Background: Stromal stem cells are actively studied as a novel ad-
junct therapy after HSCT. Safety of mesenchymal stromal cells
was shown in early phase clinical trials with benefit for engraftment
and treatment of acute or steroid refractory GVHD (Lazarus 2005,
LeBlanc 2008, Kebriaei 2009). Phase III trials have reported mixed
outcomes for MSC therapy for acute or steroid refractory GVHD
(Martin 2010, Prasad 2010). Multipotent adult progenitor cells
(MultiStem) is a stromal stem cell source with similar immune-
modulatory activity as MSC and can be manufactured to clinical
scale allowing all patients on an individual study to be treated with
uniform allogeneic cell product from a universal donor. Pre-clinical
studies have demonstrated safety for iv infusion of MultiStem and
survival benefit in a haploidentical acute GVHD rat model when
used in a prophylactic manner (Kovacsovics 2008, 2009).
Methods: The primary goal of this open label Phase I clinical dose
escalation study is to assess safety of MultiStem in adult hematolog-
ical malignancy patients when administered shortly after allogeneic
HSCT. Patients with AML, ALL, CML, or MDS are enrolled in ei-
ther one of two study arms for MultiStem infusion at 1, 5 or 10
